🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#DYK Parkinson’s disease is the second most common neurodegenerative disorder? April is #Parkinsons Awareness Month – an important reminder to educate ourselves about symptoms, risk factors, and the impact Parkinson’s has on patients and families. #ParkinsonsAwareness

#NEWS: Arvinas Announces Results from the PROTAC Estrogen Receptor Degrader Phase 3 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Learn More: bit.ly/3Gh0zn4

#NEWS: Arvinas Shares New Preclinical Combination Data for their PROTAC BCL6 Degrader at the 2025 American Association for Cancer Research Annual Meeting. Learn More: bit.ly/3ECUUHs $ARVN

#NEWS: Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025. Learn More: bit.ly/3Ym7EZz $ARVN

#NEWS: Today Arvinas shared its Q1 2025 earnings and a business update. Read the release here: bit.ly/3EIEZY8

We were honored to welcome Trish Michelle from the breasties to #Arvinas. Trish shared her personal experience with breast cancer and how it inspired her to advocate for others and help build a powerful community of support, education, and empowerment. Thank you, Trish, for

Today, we pause to remember and honor those who made the ultimate sacrifice serving our country. Their courage and dedication will never be forgotten. #MemorialDay

We’re proud to join @Pfizer today at #ASCO25 for a late-breaking oral presentation sharing results from a Phase 3 clinical trial for patients with ER+/HER2- advanced #BreastCancer. These data were simultaneously published in NEJM. Learn more: bit.ly/45ARgst

Today is #NationalCancerSurvivorsDay– a day to honor survivors and reaffirm the ongoing support they deserve. We recognize the critical need for expanded resources, continued research, and greater awareness to enhance quality of life during and after cancer treatment. Together,

Happy #PrideMonth! At Arvinas, we celebrate and support the LGBTQ+ community by fostering an environment of inclusion, authenticity, and belonging each and every day. We stand proudly with our LGBTQ+ colleagues, partners, and communities in the ongoing pursuit of equality and

June is Alzheimer’s & Brain Awareness Month—a reminder that 7.2M+ Americans aged 65+ are living with Alzheimer’s. At Arvinas, our purpose drives our commitment to pioneering targeted protein degradation therapies for neurodegenerative diseases. #AlzheimersAwarenessMonth

#NEWS: We’re pleased to announce our first ever New Drug Application submitted to the U.S. FDA with our partner at @Pfizer. The submission is based on a global, randomized Phase 3 trial for the potential treatment of ESR1-mutated ER+/HER2- advanced or metastatic #BreastCancer.

#NEWS: Arvinas Presents Preclinical Data for its PROTAC BCL6 Degrader at the European Hematology Association 2025 Congress. Learn more: bit.ly/4kDc6vY $ARVN

Earlier this month, #TeamArvinas gathered for our annual company picnic and it served as the perfect opportunity to take a break from busy days in the lab and at our desks. We are always grateful for the opportunity to connect with each other in meaningful ways. The team enjoyed

Charlie leads Medical Writing, Data Management, & Clinical Operations, helping advance potential therapies from clinical candidate nomination through trial execution. His team drives timelines & budgets, while making sure our clinical trials are thoughtfully designed, rigorously

Happy Fourth of July! Today we’re celebrating innovation, collaboration, and independence. 🇺🇸 #IndependenceDay

#ICYMI: Our CMO Dr. Noah Berkowitz shares his reflections from #ASCO25—highlighting advances in breast cancer care and our pioneering protein degradation therapies. #CancerResearch #Innovation linkedin.com/feed/update/ur…

#NEWS: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan. Learn more: bit.ly/4lDn0lC

As pioneers in targeted protein degradation, we’re advancing our PROTAC Discovery Engine platform, which creates PROTACs that are designed to harness the cell’s natural disposal system to eliminate disease-causing proteins. That work requires not only breakthrough technology,